Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Stock Quote & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Healthcare Biotechnology

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

The Power Play by The Market Herald

{{currentVideo.videoCaption}}

{{currentVideo.headline}}

{{currentVideo.link1Text}}

{{currentVideo.link2Text}}

< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (CSE:AGN)

Fundamentals Snapshot (CSE:AGN)

"While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies, we announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving."

Christopher J. Moreau, CEO

Current News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) receives patent for Ifenprodil

John Ballem 3 days ago

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire 3 days ago

Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants

Azuka Onwuka 4 days ago

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

GlobeNewswire 4 days ago

Algernon Pharmaceuticals (CSE:AGN) announces public offering of units

John Ballem 9 days ago

Algernon Pharmaceuticals Announces Public Offering of Units

GlobeNewswire 10 days ago

View More News ››

"Ifenprodil’s anti-tumour effect in this study is very impressive when you consider it does not appear to have the serious side effects typically seen with other chemotherapy agents.Our business plan is to have upwards of three to four Phase 2 trials underway in 2022 and we are very pleased to be adding Ifenprodil with a cancer indication to our pipeline.."

Christopher J. Moreau, CEO

Opinion & Analysis (CSE:AGN)

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

Dave Jackson June 16, 2021

Flying Under the Radar with a Possible COVID-19 Treatment

Stockhouse Editorial September 9, 2020

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Streetwise Reports May 29, 2020

Buzz on the Bullboards: Coronavirus, Esports, and Uranium Plays

Omri Wallach April 16, 2020

Buzz on the Bullboards: HOT Coronavirus Healthcare Stocks

Omri Wallach March 19, 2020

View More Opinion ››

"We are very pleased to be expanding our Ifenprodil cancer research program to include SCLC,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We also welcome Dr. William North to help us lead the investigation of Ifenprodil’s potential as a new non-toxic cancer therapy."

Christopher J. Moreau, CEO

Bullboard Posts (CSE:AGN)

RE:RE:Longtime Shareholder Says It's Time To Dump Algernon

Says the moron who hasn't a clue what he/she's talking about here or at ceo.ca with a 3 stooges following plus Shemp. I've...

C10H12N2 - 17 hours ago

RE:Longtime Shareholder Says It's Time To Dump Algernon

Breaking news!! Long time bag holder who has been trying to con you into buying gives up

TheBearInTheWoods - 21 hours ago

Longtime Shareholder Says It's Time To Dump Algernon

I'm dumping the last of my shares held since 2016 once news drops for the Topline Data Readout. I careless what the price will be at...

C10H12N2 - 1 day ago

RE:Recent Trading

You are STILL going after market makers as if that's the problem with Algernon? Just WOW!

C10H12N2 - 1 day ago

Recent Trading

Since 10:30 yesterday there have been a total of 3 trades and total volume of 400 shares. Bring the market price down by 75 cents...

nodaytrader - 1 day ago

Best way to buy Adderall online with credit card & Get 30% C

Best way to buy Adderall online with credit card & Get 30% Cashback Attention deficit hyperactive disorder is one kind of...

keviss - 1 day ago

View more Bullboard ››

follow C.AGN on

PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

Video Q&A With CEO Christopher J. Moreau

Download the latest Investor Presentation

Algernon Pharmaceuticals | The Power Play

{{currentVideo.videoCaption}}

{{currentVideo.headline}}

{{currentVideo.link1Text}}

{{currentVideo.link2Text}}

< Previous Video {{moreVideoText}} Next Video >

TWITTER

FACEBOOK

IR CONTACT

info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com